Esteve Pharmaceuticals, S.a.

This global registry follows 500 children and teens with severe primary IGF-1 deficiency who are taking or will take Increlex® (mecasermin). The goal is to monitor long-term safety and side effects over at least 5 years after treatment ends. It is an observational study, meaning …